Neurology News

A Bay Area biopharmaceutical firm has announced positive results from its phase 1 clinical trial in healthy volunteers of a novel PDE4 inhibitor being developed to treat those with cognitive impairment associated with schizophrenia.

Dementia risk decreases among patients with rheumatoid arthritis treated with biologic disease-modifying antirheumatic drugs, according to a systematic review and meta-analysis published in RMD Open.

Wearable accelerometers may be a reliable tool to track disease progression in patients with amyotrophic lateral sclerosis, researchers wrote in The Lancet.

The FDA has approved Ingrezza sprinkle capsules to treat adults with Huntington’s disease chorea or tardive dyskinesia, according to a press release from the manufacturer.

In the rapidly evolving landscape of investments, it is crucial for physicians to stay informed about alternative asset classes, such as cryptocurrency.

DENVER — Daily treatment with a suspension of gold crystals was linked to improved outcomes at 96 weeks for those with stable relapsing multiple sclerosis, according to a speaker at the American Academy of Neurology annual meeting.

Those who live in rural areas face a higher risk for dying early from preventable deaths, but primary care providers can implement strategies to reduce these disparities, experts said during a CDC press conference.

Labcorp and Quest Diagnostics have both announced the availability of blood-based biomarker testing for Alzheimer’s disease, one which detects glial fibrillary acidic protein and another for phosphorylated tau.

The FDA has approved an abbreviated new drug application for naloxone hydrochloride nasal spray, paving the way for the opioid overdose treatment to be available without a prescription.

DENVER — Self-discovery is the first step in tackling risk factors that lead to burnout, according to a speaker at the American Academy of Neurology annual meeting.